FOSTER CITY, Calif. (AP) -- Gilead Sciences Inc., a drug research company, said Tuesday it has agreed to acquire privately held biotechnology company Calistoga Pharmaceuticals Inc. for $375 million, expanding its research capabilities into cancer-fighting drugs.
Seattle-based Calistoga could earn up to an additional $225 million if certain milestones are achieved.
Gilead, which has specialized in HIV drugs and developed the flu fighting drug Tamiflu, anticipates closing the deal in the second quarter, subject to satisfaction of certain conditions. The company plans to finance the acquisition through available cash on hand.
Calistoga focuses on the development of medicines to treat cancer and inflammatory diseases. It is researching a drug, CAL-101, that may help fight non-Hodgkin's lymphoma and help treat in elderly patients a specific type of leukemia.
"Oncology remains an area of significant unmet medical need and our increased understanding of the genetic basis of cancer allows for the development of disease specific targeted therapies," said Gilead's Chief Scientific Officer Norbert W. Bischofberger. "We are very encouraged by emerging clinical data for CAL-101, and this compound could represent an advance for the treatment of certain hematological cancers."
Shares of Gilead Sciences fell 33 cents to $38.97.
Seattle-based Calistoga could earn up to an additional $225 million if certain milestones are achieved.
Gilead, which has specialized in HIV drugs and developed the flu fighting drug Tamiflu, anticipates closing the deal in the second quarter, subject to satisfaction of certain conditions. The company plans to finance the acquisition through available cash on hand.
Calistoga focuses on the development of medicines to treat cancer and inflammatory diseases. It is researching a drug, CAL-101, that may help fight non-Hodgkin's lymphoma and help treat in elderly patients a specific type of leukemia.
"Oncology remains an area of significant unmet medical need and our increased understanding of the genetic basis of cancer allows for the development of disease specific targeted therapies," said Gilead's Chief Scientific Officer Norbert W. Bischofberger. "We are very encouraged by emerging clinical data for CAL-101, and this compound could represent an advance for the treatment of certain hematological cancers."
Shares of Gilead Sciences fell 33 cents to $38.97.